| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Hainan Huluwa Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.75 |
| 52 Week High | CN¥20.09 |
| 52 Week Low | CN¥9.51 |
| Beta | 0.66 |
| 11 Month Change | -12.48% |
| 3 Month Change | -22.68% |
| 1 Year Change | -35.60% |
| 33 Year Change | -66.17% |
| 5 Year Change | n/a |
| Change since IPO | 30.52% |
Recent News & Updates
Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07
Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Shareholder Returns
| 605199 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.1% | -3.7% | -2.2% |
| 1Y | -35.6% | -17.3% | -17.9% |
Return vs Industry: 605199 underperformed the CN Pharmaceuticals industry which returned -17.3% over the past year.
Return vs Market: 605199 underperformed the CN Market which returned -17.9% over the past year.
Price Volatility
| 605199 volatility | |
|---|---|
| 605199 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 605199's share price has been volatile over the past 3 months.
Volatility Over Time: 605199's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,468 | Jinping Liu | www.huluwayaoye.com |
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other therapeutic in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products.
Hainan Huluwa Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 605199 fundamental statistics | |
|---|---|
| Market cap | CN¥3.90b |
| Earnings (TTM) | CN¥94.97m |
| Revenue (TTM) | CN¥1.81b |
41.1x
P/E Ratio2.2x
P/S RatioIs 605199 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 605199 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.81b |
| Cost of Revenue | CN¥890.16m |
| Gross Profit | CN¥918.17m |
| Other Expenses | CN¥823.20m |
| Earnings | CN¥94.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 50.77% |
| Net Profit Margin | 5.25% |
| Debt/Equity Ratio | 108.0% |
How did 605199 perform over the long term?
See historical performance and comparison